Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Stryker (SYK – Research Report) today and set a price target of $380.00. The company’s shares opened today at $333.58.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 5.8% and a 51.84% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and Conmed.
In addition to Piper Sandler, Stryker also received a Buy from Wells Fargo’s Larry Biegelsen in a report issued today. However, on the same day, JMP Securities maintained a Hold rating on Stryker (NYSE: SYK).
Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.82 billion and a net profit of $1.14 billion. In comparison, last year the company earned a revenue of $5.2 billion and had a net profit of $563 million
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in February 2024, Ronda Stryker, a Director at SYK bought 4,355.00 shares for a total of $353,364.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker (SYK) Company Description:
Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.
